描述
This granule formulation combines the amino acids L?aspartate and L?ornithine to support hepatic ammonia detoxification via the urea cycle. Commonly used in preclinical research on liver disease, encephalopathy prevention, and metabolic liver protection. Dissolve each sachet in water or juice and administer orally under controlled experimental conditions.
Product Specifications
Parameter | Details |
---|---|
Product Name | Compound L?Aspartate L?Ornithine Granules (Rigan) |
Active Ingredients | L?Aspartate, L?Ornithine |
CAS Numbers | L?Aspartate: 56?84?8; L?Ornithine: 70?26?8 |
Formulation | Oral granules |
Dosage per Sachet | 3?g |
Quantity per Box | 21 sachets |
Dosage Form | Powder for oral suspension |
NMPA Approval No. | H20090160 |
Drug Standard Code | 86901957000047 |
Manufacturer | Wuhan Qirui Pharmaceutical Co., Ltd. |
Barcode | Not yet assigned; contact pharmacist |
Shelf Life | 30 months |
Storage Conditions | Store below 25?°C, in dry, light?protected area |
Intended Use | Research into hepatic hyperammonemia and liver support |
Product appears as a white or off-white granule with a slightly sweet-sour taste.
Mechanism of Action
L?Ornithine and L?Aspartate enhance ammonia detoxification by activating the urea cycle and promoting glutamine synthesis, thereby reducing circulating blood ammonia—a key factor in hepatic encephalopathy.
Research & Application Areas
-
Hyperammonemia management in acute and chronic liver disease models
-
Hepatic encephalopathy prevention studies
-
Non?alcoholic fatty liver disease (NAFLD) research
-
Urea cycle support and nitrogen metabolism experiments
-
Comparative studies with intravenous formulations
Studies show oral L?ornithine?L?aspartate granules are effective and safe, improving liver enzyme profiles and reducing ammonia levels in metabolic liver disorders
Safety & Handling
-
Adverse Effects: Rare mild nausea, vomiting, or bloating; symptoms typically resolve upon discontinuation .
-
Contraindications: Allergy to amino acids or severe renal impairment (serum creatinine >3 mg/dL).
-
Administration: Dissolve granule in water/juice, take 1–3 times daily (usually 3?g each dose), post-meal. Dosing may be adjusted based on experimental protocol.
-
Handling: Use gloves and lab coat; avoid ingestion outside research contexts.
-
Storage: Store granules sealed and protected from moisture and light.
Core Keywords
aspartate ornithine granules, H20090160, hyperammonemia research, urea cycle support, liver detox granules, Rigan granules wholesale, research-grade ornithine aspartate
Research Use Disclaimer
This product is for research and experimental use only. Not approved for therapeutic, diagnostic, or clinical applications. Misuse may pose health or legal risks. Use only under institutional oversight and according to local regulations.
评价
目前还没有评价